Hybrid PET/MR in the Therapy of Cervical Cancer

Hybrid PET/MR in the Therapy of Cervical Cancer: A Pilot Study

This is a two arm, single center feasibility study of 20 patients with non-metastatic cervical cancer managed with surgery and/or chemoradiation therapy at UNC Hospitals. Subjects will undergo PET/MRI scans before, during (chemoradiation group only), and after treatment.

The primary purpose of this study is to evaluate the feasibility of obtaining complete and interpretable hybrid PET/MR images for patients diagnosed with cervical cancer.

Inclusion Criteria:

• ≥ 18 years of age
• Biopsy-proven, previously untreated squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the uterine cervix
• Clinically visible lesion at least FIGO stage Ib or AJCC 7th edition T1b
• Scheduled to undergo standard of care PET/CT for baseline assessment of disease
• Anticipated to be eligible for curative intent therapy (surgery of chemoradiation therapy) as determined by the patient's primary oncologist
• If female of child-bearing potential, negative serum or urine pregnancy test ≤ 7 dats prior to first PET/MRI
• Informed consent reviewed and signed

Exclusion Criteria:

• History of sever reaction to contrast-enhanced CT scan
• Inability to tolerate MRI (e.g., inability to lie flat > 1 hour)
• Presence of pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes
• Poorly controlled diabetes mellitus
• Creatinine > 1.4 mg/dL or GFR < 30 mL/min
• Body Mass Index (BMI) > 35
• Active vaginal bleeding requiring packing and emergent radiation therapy
• Pregnant or lactating female
• History of a prior malignancy within past 5 years, unless disease free for ≥ 3 years
• Substance abuse, medical, psychological, or social conditions that may interfere with study participation